M. Mizobuchi, J.L. Finch, D.R. Martin, E. Slatopolsky 

Slides:



Advertisements
Similar presentations
M. Mizobuchi, J.L. Finch, D.R. Martin, E. Slatopolsky 
Advertisements

Volume 55, Issue 2, Pages (February 1999)
Volume 60, Issue 6, Pages (December 2001)
Volume 70, Issue 3, Pages (August 2006)
Tranilast attenuates connective tissue growth factor-induced extracellular matrix accumulation in renal cells  W. Qi, X. Chen, S. Twigg, T.S. Polhill,
Renal vitamin D receptor expression and vitamin D renoprotection
Sodium thiosulfate prevents vascular calcifications in uremic rats
Volume 70, Issue 4, Pages (August 2006)
Volume 69, Issue 8, Pages (April 2006)
Volume 67, Issue 2, Pages (February 2005)
Volume 72, Issue 1, Pages (July 2007)
Dysregulation of renal vitamin D metabolism in the uremic rat
Volume 85, Issue 5, Pages (May 2014)
Volume 75, Issue 10, Pages (May 2009)
M.H.A. Baccora, P. Cortes, C. Hassett, D.W. Taube, J. Yee 
Differential effects of 19-nor-1,25-(OH)2D2 and 1α-hydroxyvitamin D2 on calcium and phosphorus in normal and uremic rats  Eduardo Slatopolsky, Mario Cozzolino,
Volume 82, Issue 12, Pages (December 2012)
Volume 60, Issue 6, Pages (December 2001)
Volume 64, Issue 2, Pages (August 2003)
Left ventricular hypertrophy in renal failure
Intestinal phosphate absorption in a model of chronic renal failure
Volume 72, Issue 6, Pages (September 2007)
Volume 72, Issue 8, Pages (October 2007)
Volume 70, Issue 11, Pages (December 2006)
D. Coyne  Kidney International  Volume 69, Pages S1-S3 (May 2006)
Paricalcitol therapy for secondary hyperparathyroidism in patients on maintenance hemodialysis previously treated with calcitriol: A single-center crossover.
Volume 71, Issue 11, Pages (June 2007)
Volume 72, Issue 8, Pages (October 2007)
Chemical and hormonal determinants of vascular calcification in vitro
Enlightenment on liver lanthanum exposure
Metabolic acidosis inhibits soft tissue calcification in uremic rats
Volume 55, Issue 2, Pages (February 1999)
Volume 74, Issue 10, Pages (November 2008)
Volume 70, Issue 12, Pages (December 2006)
J. Radhakrishnan, G. Markowitz, D.J. Cohen  Kidney International 
E. Neven, S. Dauwe, M.E. De Broe, P.C. D'Haese, V. Persy 
Role of vitamin D receptor activators on cardiovascular risk
Volume 73, Issue 6, Pages (March 2008)
The third World Kidney Day: Looking back and thinking forward
Volume 69, Issue 12, Pages (June 2006)
Volume 69, Issue 3, Pages (February 2006)
Volume 70, Issue 6, Pages (September 2006)
Volume 69, Issue 10, Pages (May 2006)
Volume 69, Issue 2, Pages (January 2006)
Acute phosphate nephropathy
Treatment with pyrophosphate inhibits uremic vascular calcification
Volume 79, Issue 5, Pages (March 2011)
Organ transplantation goes to the movies
Sclerosing encapsulating peritonitis in a 47-year-old woman
Volume 72, Issue 3, Pages (August 2007)
Volume 72, Issue 2, Pages (July 2007)
Quiz Page June 2009 American Journal of Kidney Diseases
Volume 70, Issue 3, Pages (August 2006)
Volume 70, Issue 3, Pages (August 2006)
Volume 71, Issue 9, Pages (May 2007)
Advisory about gadolinium calls for caution in the treatment of uremic patients with lanthanum carbonate  S. Aime, C. Canavese, P. Stratta  Kidney International 
Recent developments in the management of secondary hyperparathyroidism
Volume 70, Issue 5, Pages (September 2006)
Volume 76, Issue 1, Pages (July 2009)
Volume 72, Issue 11, Pages (December 2007)
The International Pediatric Peritonitis Registry: Starting to walk
Increased fetuin-A levels following treatment with a vitamin D analog
Volume 60, Issue 5, Pages (November 2001)
Control of uremic bone disease: Role of vitamin D analogs
Volume 55, Issue 4, Pages (April 1999)
Volume 61, Issue 4, Pages (April 2002)
Volume 54, Issue 6, Pages (January 1998)
Volume 87, Issue 6, Pages (June 2015)
Morphology of the heart and arteries in renal failure
Volume 75, Issue 2, Pages (January 2009)
Presentation transcript:

Differential effects of vitamin D receptor activators on vascular calcification in uremic rats  M. Mizobuchi, J.L. Finch, D.R. Martin, E. Slatopolsky  Kidney International  Volume 72, Issue 6, Pages 709-715 (September 2007) DOI: 10.1038/sj.ki.5002406 Copyright © 2007 International Society of Nephrology Terms and Conditions

Figure 1 Aortic Ca content in normal rats and 5/6 nephrectomized uremic rats treated with vehicle (UC), 0.04 μg/kg of calcitriol (1,25D3), 0.16 μg/kg of doxercalciferol (1αD2), or paricalcitol (19-nor). Each drug was given intraperitoneally three times a week for 1 month. Values are mean±s.e.m. (n=6 or 7). P<0.0001 by analysis of variance. **P<0.01 versus UC; ##P<0.01 versus 19-nor by post hoc, Scheffe test. Kidney International 2007 72, 709-715DOI: (10.1038/sj.ki.5002406) Copyright © 2007 International Society of Nephrology Terms and Conditions

Figure 2 Representative microphotograph of von Kossa staining of aorta from uremic rats treated with vehicle (UC), 0.04 μg/kg of calcitriol (1,25D3), 0.16 μg/kg of doxercalciferol (1αD2), or paricalcitol (19-nor). Each drug was given intraperitoneally three times a week for 1 month. Original magnification at × 400. Kidney International 2007 72, 709-715DOI: (10.1038/sj.ki.5002406) Copyright © 2007 International Society of Nephrology Terms and Conditions

Figure 3 Effects of 0.10 μg/kg of doxercalciferol (1αD2) or 0.24 μg/kg of paricalcitol (19-nor) on serum levels of (a) ionized Ca, (b) total Ca, (c) P, and (d) Ca × P product in uremic rats. Each drug was given intraperitoneally three times a week for 1 month. Values are mean±s.e.m. (n=6). #P<0.05 versus 19-nor by non-paired t-test. Kidney International 2007 72, 709-715DOI: (10.1038/sj.ki.5002406) Copyright © 2007 International Society of Nephrology Terms and Conditions

Figure 4 Effects of 0.10 μg/kg of doxercalciferol (1αD2) or 0.24 μg/kg of paricalcitol (19-nor) on aortic Ca content in uremic rats. Each drug was given intraperitoneally three times a week for 1 month. Values are mean±s.e.m. (n=6). ##P<0.01 versus 19-nor by non-paired t-test. Kidney International 2007 72, 709-715DOI: (10.1038/sj.ki.5002406) Copyright © 2007 International Society of Nephrology Terms and Conditions

Figure 5 Effects of 0.04 μg/kg of calcitriol (1,25D3), 0.10 μg/kg of doxercalciferol (1αD2), or 0.16 μg/kg of paricalcitol (19-nor) on Runx2 mRNA expression levels in aorta from uremic rats. Runx2 mRNA levels were analyzed by real-time RT-PCR technique. Each drug was given intraperitoneally three times a week for 1 month. Values are mean±s.e.m. (n=6). P<0.01 by analysis of variance. *P<0.05 versus UC; ••P<0.01 and •P<0.05 versus 19-nor by post hoc, Scheffe test. Kidney International 2007 72, 709-715DOI: (10.1038/sj.ki.5002406) Copyright © 2007 International Society of Nephrology Terms and Conditions

Figure 6 Effects of 0.04 μg/kg of calcitriol (1,25D3), 0.10 μg/kg of doxercalciferol (1αD2), or 0.16 μg/kg of paricalcitol (19-nor) on mRNA expression levels in aorta from uremic rats. Osteocalcin mRNA levels were analyzed by real-time RT-PCR technique. Each drug was given intraperitoneally three times a week for 1 month. Values are mean±s.e.m. (n=6). P<0.01 by analysis of variance. **P<0.01 and *P<0.05 versus UC; ••P<0.01 and •P<0.05 versus 19-nor by post hoc, Scheffe test. Kidney International 2007 72, 709-715DOI: (10.1038/sj.ki.5002406) Copyright © 2007 International Society of Nephrology Terms and Conditions

Figure 7 Representative microphotograph of immunohistochemistry for Runx2 or osteocalcin in aorta from uremic rats treated with 0.10 μg/kg of doxercalciferol (1αD2) or 0.16 μg/kg of paricalcitol (19-nor). Each drug was given intraperitoneally three times a week for 1 month. Original magnification at (a) × 100 and (b) × 200. Kidney International 2007 72, 709-715DOI: (10.1038/sj.ki.5002406) Copyright © 2007 International Society of Nephrology Terms and Conditions